BC Innovations | Mar 19, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-455-5p (miR-455-5p); adenosine deaminase RNA-specific (ADAR; ADAR1)

Cancer INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting wild-type miR-455-5p or stimulating ADAR1 activity could help prevent metastatic melanoma. In normal cells, the RNA-editing enzyme ADAR1 converts adenosine to inosine at two positions...
BC Innovations | Nov 14, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Fragile X syndrome Cytoplasmic polyadenylation element binding protein 1 (CPEB1) Mouse studies suggest inhibiting CPEB1 could help treat fragile X syndrome. In a mouse model...
Items per page:
1 - 2 of 2